Add to ORKGHouten, the Netherlands. Published online ahead of print at www.jco.org on July 8, 2013. Supported by Eli Lilly. Authors ’ disclosures of potential con-flicts of interest and author contribu-tions are found at the end of this article. Clinical trial information: NCT00789373
Introduction:The PARAMOUNT Phase III trial showed that maintenance pemetrexed after pemetrexed plus ...
AbstractObjectivesThis single-arm multicenter Phase II study investigated the efficacy and safety of...
INTRODUCTION: This study compared survival without toxicity in patients with advanced, nonsquamous n...
Introduction:The PARAMOUNT phase III trial demonstrated that pemetrexed continuation maintenance sig...
TRIAL REGISTRATION: Trial Registry: Clinicaltrials.gov REGISTRATION NUMBER: NCT00789373 TRIAL ABBREV...
The phase III PROCLAIM study evaluated overall survival (OS) of concurrent pemetrexed-cisplatin and ...
AbstractIntroductionIn the PARAMOUNT (“A Phase 3, Double-Blind, Placebo-Controlled Study of Maintena...
IntroductionIn a phase III, randomized, double-blind study (PARAMOUNT), maintenance pemetrexed demon...
PubMed ID: 19473833Background: In a large phase III study, cisplatin and pemetrexed had non-inferior...
BACKGROUND: Several studies have shown the efficacy, tolerability, and ease of administration of pem...
WOS: 000270645700017PubMed ID: 19473833Background: In a large phase III study, cisplatin and pemetre...
Aim: To evaluate treatment patterns and overall survival (OS) in real world metastatic non-squamous ...
Long-term use of continuation maintenance pemetrexed was well tolerated; resource use was low, corre...
Background: Using data from a large phase III study of previously treated advanced non-small-cell lu...
Introduction: This study compared survival without toxicity in patients with advanced, nonsquamous n...
Introduction:The PARAMOUNT Phase III trial showed that maintenance pemetrexed after pemetrexed plus ...
AbstractObjectivesThis single-arm multicenter Phase II study investigated the efficacy and safety of...
INTRODUCTION: This study compared survival without toxicity in patients with advanced, nonsquamous n...
Introduction:The PARAMOUNT phase III trial demonstrated that pemetrexed continuation maintenance sig...
TRIAL REGISTRATION: Trial Registry: Clinicaltrials.gov REGISTRATION NUMBER: NCT00789373 TRIAL ABBREV...
The phase III PROCLAIM study evaluated overall survival (OS) of concurrent pemetrexed-cisplatin and ...
AbstractIntroductionIn the PARAMOUNT (“A Phase 3, Double-Blind, Placebo-Controlled Study of Maintena...
IntroductionIn a phase III, randomized, double-blind study (PARAMOUNT), maintenance pemetrexed demon...
PubMed ID: 19473833Background: In a large phase III study, cisplatin and pemetrexed had non-inferior...
BACKGROUND: Several studies have shown the efficacy, tolerability, and ease of administration of pem...
WOS: 000270645700017PubMed ID: 19473833Background: In a large phase III study, cisplatin and pemetre...
Aim: To evaluate treatment patterns and overall survival (OS) in real world metastatic non-squamous ...
Long-term use of continuation maintenance pemetrexed was well tolerated; resource use was low, corre...
Background: Using data from a large phase III study of previously treated advanced non-small-cell lu...
Introduction: This study compared survival without toxicity in patients with advanced, nonsquamous n...
Introduction:The PARAMOUNT Phase III trial showed that maintenance pemetrexed after pemetrexed plus ...
AbstractObjectivesThis single-arm multicenter Phase II study investigated the efficacy and safety of...
INTRODUCTION: This study compared survival without toxicity in patients with advanced, nonsquamous n...